Aktis Oncology Adds ADC Veteran Gormley to Board Amid Leadership Transition
Event summary
- Aktis Oncology appointed Glenn Gormley, MD, PhD, as independent director and co-chair of its new Science and Technology Committee, effective April 16, 2026.
- Gormley brings 30+ years of biopharmaceutical leadership, including global R&D roles at Daiichi Sankyo, AstraZeneca, Novartis, and Merck.
- Current board members Helen Kim and Oleg Nodelman will step down effective May 20, 2026, after five years of service.
- Aktis' miniprotein radioconjugate platform targets multiple solid tumors, with lead candidate AKY-1189 focusing on Nectin-4 expressing cancers.
The big picture
Aktis Oncology's appointment of Glenn Gormley, a veteran in antibody-drug conjugate (ADC) development, signals a strategic push to enhance its targeted radiopharmaceutical platform. This move comes as the company transitions from early-stage investment backing to a clinical-stage, publicly traded entity. The addition of Gormley's expertise in global biopharmaceutical leadership may position Aktis to compete more effectively in the rapidly evolving oncology market, particularly as it seeks to broaden the application of its technology beyond current platform limitations.
What we're watching
- Strategic Alignment
- How Gormley's ADC expertise will influence Aktis' radiopharmaceutical development strategy.
- Leadership Impact
- Whether the new board composition can accelerate Aktis' clinical and corporate milestones.
- Pipeline Progress
- The pace at which Aktis advances its miniprotein radioconjugate platform across multiple tumor types.
Related topics